Provided By PR Newswire
Last update: Mar 12, 2025
NEW YORK, March 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit.
Read more at prnewswire.com25.9
+1.25 (+5.07%)
Find more stocks in the Stock Screener
Discover PACIRA BIOSCIENCES INC, an undervalued growth gem. NASDAQ:PCRX is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.
The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today.
PACIRA BIOSCIENCES INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:PCRX showcases decent financial health and profitability, coupled with an attractive price.